enoxacin has been researched along with Bone Cancer in 1 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cornaz-Buros, S | 1 |
Riggi, N | 1 |
DeVito, C | 1 |
Sarre, A | 1 |
Letovanec, I | 1 |
Provero, P | 1 |
Stamenkovic, I | 1 |
1 other study available for enoxacin and Bone Cancer
Article | Year |
---|---|
Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Enoxacin; Glyco | 2014 |